First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested. Strong cash position expected to fund operations until mid-2019.

 

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a

leader in the discovery and development of engineered cell therapies, with clinical programs in immuno-oncology, today provides an update on its recent operations and reported consolidated financial results for the twelve-month period ended 31 December 2016, prepared in accordance with IFRS.

 

Commenting on the 2016 results, Christian Homsy, CEO of Celyad, said: “2016 has been a challenging year in which our CAR-T portfolio has continued to develop, with the company building its expertise in the field of immuno-oncology, and one in which we transitioned from a focus on cardiology to being one of the most promising prospects in the field of next generation CAR-T cells.

Download press release(s)

Press release

122.29 Ko

Communiqué de presse

140.75 Ko

Conference call – audio file

17.94 Mo

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with class...

Next News

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with class...